Delpor is a clinical stage life sciences company that utilizes innovative drug delivery technologies to develop new therapeutic products which are based on approved drugs. Delpor’s technologies enable the sustained release of drugs through a small, non-mechanical (passive), subcutaneous implant device. The device is implanted during a simple, 10-minute, in-office, procedure using local anesthetic.

We have the capability to deliver small molecules, peptides, and proteins, within a predefined therapeutic window over several months while maintaining zero-order release pharmacokinetics.

The benefits of such delivery include improved patient adherence to the medication, as well as patient convenience in the case where frequent injections are required. Our delivery technologies also result in fewer AEs and improved efficacy due to a smoother pharmacokinetic profile without any peaks or troughs.

We are currently pursuing 6-12 month formulations of several drugs targeting numerous chronic conditions.